FAP, May 12 / PRNewswire-FirstCall-Asianet /-- Lisheng Pharmaceutical announced that its subsidiary Tianjin Central Pharmaceutical Co., Ltd. received a "notice of approval for Supplementary Drug Application" issued by the State Drug Administration on atenolol tablets 25mg and 12.5mg. The drug is the first in China to pass the consistency evaluation of generic drug quality and efficacy. Atenolol tablets are mainly used in the treatment of hypertension, angina pectoris and myocardial infarction, as well as arrhythmia, hyperthyroidism and pheochromocytoma.